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Abstract
Background: A large number of epidemiological studies have evaluated the association between Epstein-Barr virus
infection and breast carcinoma risk but results have been inconsistent.
Methodology: Research using the polymerase chain reaction technique for detecting the Epstein-Barr virus was selected; 24
studies and 1535 cases were reviewed. Information on the study populations, sample types, publication calendar period and
histological types of breast carcinoma were collected. An unconditional logistic regression model was used to analyze
potential parameters related to the Epstein-Barr virus prevalence. A Kappa test was used to evaluate the consistency in
detecting different Epstein-Barr virus DNA regions. Nine studies that included control groups and 1045 breast cancer cases
were adopted in this meta-analysis.
Conclusions: We found that 29.32% of the patients with breast carcinoma were infected with the Epstein-Barr virus. The
prevalence of Epstein-Barr was highest in Asia (35.25%) and lowest in the USA (18.27%). Statistical analysis revealed a trend
that showed lobular breast carcinoma might have the strongest association with Epstein-Barr virus infection. This meta-
analysis showed a significant increase in breast malignancy risk in patients testing positive for the Epstein-Barr virus
(OR=6.29, 95% CI=2.13–18.59). This result suggests that an Epstein-Barr virus infection is statistically associated with
increased breast carcinoma risk.
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Introduction
Virusesareinvolved inthe development of various cancers [1]. In
1995, the Epstein-Barr virus (EBV), an ubiquitous herpes virus, was
found in21% of91breastcancers [2]. Sincethen,a large numberof
studies have detected EBV infection in patients with breast
carcinoma. A series of studies that adopted non-breast-cancer
control groups have also been performed [2–11], and several
mechanisms and hypotheses about the association between EBV
infection and breast carcinoma have been developed [1,12–17].
Someresearchers believed that EBV infectionmay play a role in the
early stages of breast carcinogenesis and elevate breast cancer risk
[16]. Moreover, EBV infection might be a latent factor in the
development of certain types of breast carcinoma [17]. However,
statistical data from studies have varied widely. This inconsistency
could be largely attributable to several problems: technical
challenges in detecting and localizing the EBV in tumor cells, study
designs that involved a specifichistological type ofbreastcarcinoma,
and the lack of an epidemiological perspective that could clarify the
inconsistencies in EBV prevalence across studies [18].
This study collected published information on EBV prevalence
in breast carcinoma and explored the potential associations
between EBV infection and breast cancer risk.
Methods
Searching and Selection
Medline and PubMed were searched for citations published
from 1990 to September 2010 using the MeSH terms ‘‘Epstein-
Barr virus,’’ ‘‘human,’’ ‘‘breast carcinoma’’ or ‘‘breast cancer’’.
Additional relevant references cited in retrieved articles were
reviewed. Data extracted from studies had to meet the following
criteria: (I) Studies had to use PCR-based techniques including
quantitative PCR (QPCR) for detecting the EBV DNA in breast
tissues. Studies based on cell lines or cells were not included, and
the samples in the PCR assays could not have been preselected by
other technologies such as immunohistochemistry or in-situ
hybridization. (II) Data could be only on sporadic breast
carcinoma. Studies in special groups were not included. (III) In
instances where the research data were published in more than
one article, only the publication with the most explicit description
was included. (Figure S1)
Data extraction
Data were extracted from each included study. Data included
the first author’s name, the journal, the year of publication, and
the country of origin. Data were additionally extracted regarding
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detected by each kind of primer in each type of breast carcinoma
tissues (if shown) by disease status and matching criteria if controls
were present. To avoid bias from methods used in individual
studies, only data acquired using PCR were used in the analyses.
Study characteristics and quantitative data synthesis
Our meta-analysis consisted of three parts. The first part was
an epidemiological description of the EBV prevalence in breast
carcinoma tissues and an exploration of possible parameters for
EBV infection or defection. The second part was a description
of detecting the different amplification fragments in the EBV
genome (Bam H1W, Bam H1C, EBER2, LMP1, LMP2, EBNA1,
EBNA4, BXLF1, BZLF1, BALF5, LF3, Gp220, Raji and Pol)i n
the PCR assays. The third part was a statistical pooling of the
EBV infection and breast malignancy risk estimates. The
prevalence rate and the OR were the two main parameters
for these studies.
An unconditional logistic regression model was adopted to
compare and adjust the EBV prevalence by the following
parameters: region (Asia, North Africa, North America, South
America and Europe), sample types (fresh/frozen tissue or
paraffin-embedded tissue), publication calendar period (1993–
1999, 2000–2004 and 2005–2008), and the histological types. The
effect of applying different PCR primers for detecting the EBV
DNA in tissue samples was also evaluated. A McNemar test and
Kappa test were adopted to estimate the diversity and consistency
of the outcomes among the paired data extracted from available
studies.
Fixed-effect and random-effect models were adopted to pool the
patient and control data based on Mantel-Haenszel [19] and
DerSimonian and Laird methods [20] according to the heteroge-
neity test from the studies. When heterogeneity is significant, a
random-effects model is preferred. The heterogeneity test was
performed using the x
2-based I
2 test and was considered significant
when p,0.05. Begg’s test and Harbord’s weighted linear
regression test [21] were used to evaluate the publication bias.
Analyses were performed using STATA statistical software,
Version 11.0.
Results
Epidemiological prevalence of the EBV in breast cancer
This analysis included 24 publications [2–4,6–11,22–35]. One of
these publications [10] was divided into six parts to correspond to
the six different countries or regions from where the cases were
taken (information shown in Table S1). In the first analysis, 1535
cases from sixteen countries and regions were present (Table 1),
with most cases taken from Europe (55.70%) and the Americas
(20.33%). The prevalence of the EBV ranged from 0% to 53.58%
in the selected individual studies, but the overall prevalence of the
EBV in patients diagnosed with breast carcinoma was 29.32% (95%
CI=27.05–31.66%). The EBV prevalence was the lowest in the
North American subjects (18.27%, 95% CI=14.14–23.01%) and
the highest in the Asian subjects (35.25%, 95% CI=26.82–
44.41%). Compared to the European subjects (the largest sample
size), the North American subjects (USA) demonstrated a
significantly lower prevalence of the EBV in breast cancer cases
(OR=0.48, 95% CI=0.35–0.66 and OR=0.62, 95% CI=0.44–
0.87 after adjustment). There were no significant differences in the
EBV prevalence in breast cancer by the year of publication,
although studies reported in the period 1993–1999 presented the
highest prevalence (33.33%, 95% CI=27.70–39.34). The preva-
lence of the EBV DNA was significantly lower (OR=0.46, 95%
CI=0.35–0.61) when the samples were extracted from paraffin-
embedded tissues (19.51%, 95% CI=16.21–23.15%) compared with
when they were extracted from fresh or frozen tissues (34.46%, 95%
CI=31.52–37.49%). Because there was no significant heterogeneity
by calendar year or between the European and North African
(P=0.6900) populations, these factors were excluded and the EBV
prevalence was recalculated to show that the EBV prevalence was
lowest in the paraffin-embedded tissues from the North American
subjects (10.71%, 95% CI=6.47–16.40%, data not shown).
Sixteen studies were selected and analyzed for the prevalence of
EBV infection. These studies offered clear information about the
EBV prevalence in patients diagnosed with different histological
types of breast carcinoma [2–4,6,7,9–11,22,25,26,29,30,33–35].
Patients diagnosed with lobular breast carcinoma showed a higher
prevalence of the EBV (Figure 1) than patients diagnosed with
ductal carcinoma (adjusted OR=1.792, 95% CI=1.003–3.200).
Table 1. EBV prevalence in all types of breast carcinoma cases.
Category Subcategory No. of studies No. of cases % Prevalence (%)(95% CI) Adjusted OR
c
Overall Total
a 29 1535 100 29.32 (27.05–31.66) -
Region Europe 14 855 55.70 31.70 (28.59–34.93) Ref
North America (USA) 7 312 20.33 18.27 (14.14–23.01) 0.62 (0.44–0.87)
South America 2 108 7.03 33.33 (24.55–43.05) 1.56 (0.98–2.47)
Asia
b 3 122 7.95 35.25 (26.82–44.41) 1.47 (0.91–2.40)
North Africa 3 138 8.99 31.16 (23.55–39.59) 1.09 (0.73–1.62)
Publication
calendar period
1993–1999 6 267 17.39 33.33 (27.70–39.34) Ref
2000–2004 14 850 55.38 28.35 (25.34–31.51) 0.79 (0.58–1.08)
2005–2008 9 418 27.23 28.71 (24.42–33.31) 0.83 (0.56–1.23)
DNA specimen Fresh/frozen tissue 15 1007 65.60 34.46 (31.52–37.49) Ref
Paraffin-embedded tissue 14 528 34.40 19.51 (16.21–23.15) 0.46 (0.35–0.61)
95% CI: confidence interval, OR: odds ratio.
a: One study [10] was divided into six parts because samples from six different countries were collected and tested.
b: Turkey was grouped in Asia because of its racial traits.
c: Adjusted by region, publication calendar period and DNA specimen.
doi:10.1371/journal.pone.0031656.t001
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Twenty one publications [2–10,23–29,31–35] that specified the
individual DNA primers used for EBV detection were selected.
One study [11] was excluded from this analysis due to the lack of
information about respective prevalence when detecting different
regions or genes in the EBV genome. One publication [10] was
divided into six studies as described previously. The different
primers used in the PCR assay to detect EBV DNA were
summarized and analyzed. In total, 14 different genome fragments
were amplified by respective primers (Table 2). The Bam H1W
region (12 studies, 504 cases) was the most frequently used genome
fragment for detecting EBV DNA in these studies and was used as
the reference for normalizing and adjusting the incidence
determined by the other fragments. The Bam H1C region (7
studies, 598 cases) was the next most frequently used fragment.
BXLF1 and LF3 showed the highest prevalence rate of EBV in
breast cancer, although this prevalence was based on a single study
of only 15 cases. After adjustment, BXLF1 demonstrated a
significantly higher detection. BZLF1, Raji and BALF5 showed a
0% prevalence and were included in only one study of
approximately 50 cases. EBER2 and LMP1 were included in 3
studies with over 100 cases and showed significantly higher and
lower detections of EBV, respectively. Bam H1C demonstrated a
higher but significantly insignificant prevalence rate than Bam
H1W (data shown in Table 2).
To further investigate the diversity and consistency among the
prevalence outcomes for detecting different EBV genome
fragments, six publications [2,5,8,25,29,31] with paired data were
selected for analysis (Table 3). Bam H1W is repeated 7 to 12 times
in the EBV genome, making it a good target for detection of EBV
DNA, even in a sample with a low viral copy number [5,36], and
our study supported this finding. Bam H1C, EBER2 and EBNA1
showed insignificant heterogeneity in EBV prevalence with Bam
H1W and had a relatively higher breast cancer prevalence rate
than Bam H1W. LMP1 and EBNA4 showed insignificant
heterogeneity in detecting EBV prevalence and had significantly
lower detection ability than Bam H1W. BZLF1 demonstrated an
insignificantly lower EBV detection ability while LMP1 and LMP2
Figure 1. EBV DNA prevalence in specific types of breast
carcinoma. Sixteen studies were selected and analyzed for the
prevalence of EBV infection [2–4,6,7,9–11,22,25,26,29,30,33–35]. The
EBV prevalence rate by type of breast carcinoma is as follows: ductal
(28.60%), lobular (34.78%) and other or mixed types (17.33%). Lobular
carcinoma showed a significantly higher EBV prevalence than ductal
carcinoma (adjusted OR=1.792, 95% CI=1.003–3.200, OR was adjusted
by region, publication calendar period and specimen type), indicating
that EBV infection probably increases breast carcinoma risk, especially
for some specific types of carcinoma such as lobular carcinoma,
according to available publications.
doi:10.1371/journal.pone.0031656.g001
Table 2. Different primers used for detecting EBV prevalence in PCR analyses.
Amplification fragments No. of studies
a No. of cases Prevalence Prevalence (%)(95% CI) Adjusted OR
b
Bam H1W 12 504 132 26.19 (22.40–30.26) Ref
Bam H1C
a 7 598 179 29.93 (26.29–33.78) 1.27 (0.83–1.93)
EBER2 3 141 50 35.46 (27.59–43.95) 1.74 (1.06–2.86)
LMP1 3 127 7 5.51 (2.24–11.03) 0.27 (0.12–0.59)
EBNA1 2 90 2 2.22 (0.27–7.71) 0.29 (0.05–1.64)
BXLF1 1 95 44 46.32 (36.02–56.85) 3.27 (1.79–5.98)
Pol 1 92 19 20.65 (12.92–30.36) 1.06 (0.55–2.05)
Gp220 1 57 13 22.81 (12.74–35.84) 0.15 (0.01–1.76)
LMP2 1 55 1 1.82 (0.05–9.72) 0.24 (0.03–2.18)
BZLF1 1 55 0 0 (0–6.49)c 0 (P=0.0416)
d
EBNA4 1 48 5 10.42 (3.47–22.66) 0.14 (0.04–0.47)
Raji 1 45 0 0 (0–7.87)
c 0 (P=0.0648)
d
BALF5 1 45 0 0 (0–7.87)
c 0 (P=0.0648)
d
LF3 1 15 6 40.00 (16.34–67.71) 2.53 (0.82–7.80)
95% CI: confidence interval, OR: odds ratio.
a: One study [10] was divided into six parts because samples from six different countries were tested. Three studies [11,22,30] were excluded because one [11] could not
offer the EBV DNA prevalence detected by each primer, respectively, and the others [22,30] only included 1 case.
b: adjusted by normalizing the constituent ratio of region and DNA specimen of the Bam H1W group.
c: one-sided, 97.5% confidence interval.
d: exact confidence levels not possible with zero count cells.
doi:10.1371/journal.pone.0031656.t002
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Bam H1W. All of these results were consistent with our last analysis
(Table 2), except the results from the targets with small sample
sizes. A Kappa test showed that Bam H1C and EBER2 displayed
high and very high consistency with Bam H1W in the EBV
detection. LMP1 and LMP2 demonstrated weak consistency, while
BZLF1 demonstrated no consistency with Bam H1W in the EBV
detection. Meanwhile, EBNA4 and LMP1 demonstrated moderate
consistency with each other (data shown in Table 3).
Statistical pooling of EBV infection and breast cancer
Eleven studies included non-breast cancer control groups, one of
which [27] was excluded because some of the control data were
extracted from breast cancer cell lines. Therefore, 10 studies [2–11]
wereselectedfor this meta-analysis (detailed information is shown in
Table S2), one of which [7] was excluded by the software after data
pooling due to the absence of the EBV in both patient and control
groups. The data analysis revealed high heterogeneity among these
studies (I
2=75.9%, P=0.000), so a random-effects model was
chosentoestimatethe ORafterpooling(Figure2).A 6.29-fold(95%
CI=2.13–18.59) increased breast carcinoma risk was associated
with EBV infection (the OR values with a 95% CI from individual
studies are shown in Table S3). For the sensitivity analysis, each
study was excluded by turns. After that exclusion, depending on the
heterogeneity among studies, fixed-effects or random-effects models
were adopted for analyses. All the outcomes showed a significant
association between EBV infection and increased breast carcinoma
risk, as shown in Table S4, revealinga relativelylow sensitivity. This
Table 3. Paired data of different detection fragments of EBV DNA.
Paired data of amplification fragments
No. of
cases Prevalence rate
Exact
McNemar P Agreement Kappa Z value P(.Z)
Bam H1W - Bam H1C 89 21.35%–19.10% 0.6875 93.26% 0.7812 7.48 0.0000
Bam H1W - EBER2 108 33.33%–33.33% 1.0000 100% 1.0000 10.39 0.0000
Bam H1W - LMP1 79 11.39%–2.53% 0.0156 91.14% 0.3361 3.99 0.0000
Bam H1W - EBNA1 55 7.27%–3.64% 0.5000 98.18% 0.7909 6.00 0.0000
Bam H1W - LMP2 55 7.27%–1.82% 0.0156 94.55% 0.3820 3.60 0.0002
Bam H1W - BZLF1 55 7.27%–0% 0.1250 92.73% 0.0000 not available not available
LMP1 - EBNA4 48 10.42%–10.42% 1.0000 91.67% 0.5535 3.83 0.0001
doi:10.1371/journal.pone.0031656.t003
Figure 2. Association between EBV infection and breast carcinoma risk (ORs). Ten studies that adopted non-breast-cancer control groups
[2–11] were selected for the analysis of EBV infection and human breast carcinoma risk. One [7] was excluded automatically after data pooling for the
absence of EBV DNA in both patient and control groups. Random-effects model was chosen to estimate the ORs after pooling due to the high
heterogeneity among these studies (I
2=75.9%, P=0.000). A significant, 6.29-fold (95% CI=2.13–18.59) increased breast carcinoma risk in patients
with an EBV infection was shown.
doi:10.1371/journal.pone.0031656.g002
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from a statistical perspective. To measure publication bias, a Begg’s
test and a Harbord’s weighted linear regression test (Figure 3) were
used, both of which were insignificant (P=0.917 and P=0.173,
respectively).
Discussion
Over the past few decades, the association between EBV
infection and breast carcinoma has been debated. This debate is
due, in part, to the epidemiological variation in EBV infections
[16]. The more popular viewpoint is that this controversy might be
due to differences in the methodologies or techniques used to
detect the EBV in breast samples because different assays have
different sensitivities and different standards for an ‘‘EBV positive’’
diagnosis. So far, polymerase chain reaction (PCR), immunohis-
tochemistry (IHC) and in situ hybridization (ISH) are the most
frequently used techniques to detect the EBV in breast tumors.
Correspondingly, two general targets were used in detecting EBV
in breast samples: a viral product, which includes the encoded
RNAs and proteins, and the viral genome DNA itself.
EBV-encoded small RNAs (EBERs) in situ hybridization (EBER-
ISH) is a highly sensitive method for detecting the EBV in breast
tumor tissues. However, reports have indicated that EBV gene
products, including many EBERs, may not be expressed
detectably in EBV-positive tumor cells [9,29,37] because the
targeted products are not expressed consistently in latent EBV
infection or in certain stages of infection. Additionally, the
possibility of an EBER-negative form of EBV infection has been
presented [38], which could cause false-negative results and affect
Figure 3. Estimating publication bias by Begg’s test (A) and Harbord’s weighted linear regression test (B). Begg’s test (A) was adopted for
measuring publication bias and showed a non-significant publication bias (P=0.917). Harbord’s weighted linear regression (B) also indicated a non-
significant publication bias (P=0.173).
doi:10.1371/journal.pone.0031656.g003
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1 transcripts only exist in a proportion of tumor cells, indicating the
high expression of EBERs in infected cells might not be universal
[2,10,29]. This result might additionally result in false-negative
outcomes when the infected tissue blocks did not contain many
EBER high-expression cells. In addition, false outcomes using in situ
hybridizations (ISH) to detect EBERs may arise because low levels
of expression of EBERs are nearly indistinguishable from
background staining. The same weakness occurred when detecting
the EBV by Immunohistochemical methods.
Immunohistochemistry (IHC) is also available for the detection
of viral proteins, but some viral proteins are not consistently
expressed in latent EBV infection. Though the EBV nuclear
antigen-1 (EBNA1) is expressed in all forms of viral latency, as it is
required for viral DNA replication and the maintenance of the
EBV episome in infected cells [39], some antibodies used to detect
EBNA1 produced only weak staining and could cross-react with
other proteins, resulting in false outcomes from the IHC assays
[27]. Thus immunohistochemical detection for EBNA1 is not
reliable and these false outcomes could cause bias and affect the
accuracy of our analyses.
The PCR method is a potentially important technique for
detecting EBV DNA. A few studies that combined PCR with other
detection methods such as IHC or EBER-ISH showed contradic-
tory results [6,28,31]. The controversy may be a consequence of
the different detection techniques. Nevertheless, many others
studies showed significantly correlated results [3,5,8–11,30] and
recommended the simple PCR method as the first priority for
detecting the EBV in breast tissues.
In light of the merits and drawbacks of each method, we chose
statistical data from studies which detected EBV DNA with PCR
techniques to identify the correlation between EBV infection and
breast cancer risk.
Our study showed a significant heterogeneity of EBV
prevalence (OR=0.62, 95% CI=0.44–0.87) between Europe
and the USA in breast carcinoma tissues, which indicated that
there were fewer associations between EBV infection and breast
carcinoma cases in the USA than in Europe. Reasons for this
difference are unclear but may be related to the prevalence of the
EBV and differences in testing methods and diagnostic criteria for
EBV infection in the USA. In addition, the potential influence of a
multi-cultural society and large number of migrants may play a
role in explaining this difference. The EBV prevalence in breast
carcinoma cases was slightly higher in the 1993–1999 publication
period (33.33%, 95% CI=27.70–39.34%) and then dropped to
28.35% in 2000–2004 and rose slightly to 28.71% in the last
period. These variations were insignificant. The decrease from
2000–2004 may indicate more stable data because of larger
sample sizes (850 cases versus 267 cases in 1993–1999). The
increase after 2004 was probably related to the technical
improvements in EBV DNA detection. EBV detection in fresh/
frozen tissue showed many more positive results (34.46%) than in
paraffin-embedded tissue, and the heterogeneity was statistically
significant (OR=0.46, 95% CI=0.35–0.61), indicating that a
biopsy or different slide preparation of tested specimens may yield
different results. and break DNA strands. Moreover, it is much
simpler paraffin-embedded for DNA detection. However, we did
not find paraffin-embedded tissue and fresh/frozen tissue for the
same patients, so it is difficult to conclude Normally frozen tissues
samples show higher ‘‘fidelity’’ than paraffin-embedded tissue
because some necessary processes and chemicals used to prepare
paraffin-embedded samples, such as xylene, could damage
whether fresh/frozen samples are more suitable for EBV detection
than paraffin-embedded tissue.
We collected information about the EBV prevalence in different
types of breast carcinomas with a prevalence rate of 28.60 in
ductal, 34.78% in lobular, and 17.33% in other or mixed type
breast carcinomas. The statistical analysis revealed that lobular
breast carcinoma had a higher correlation with the EBV than did
ductal carcinoma (adjusted OR=1.792, 95% CI=1.003–3.200),
though it is unclear whether this significant difference results from
biological patterns. Both lobular and ductal breast carcinoma
show a relatively higher EBV prevalence than mixed carcinomas
or other types of breast tumors. These differences in prevalence
may be because EBV infection elevates breast cancer risk in some
specific types of breast carcinoma [17]. Invasive lobular and ductal
breast cancers may have a higher association with the EBV [2].
Fourteen different EBV DNA regions or genes were detected in
breast carcinoma tissues (Table 2) and demonstrated various
detection abilities for the EBV. Bam H1W was adopted in 12
studies as a reference. Bam H1C showed similar detection rate to
Bam H1W (OR=1.27, 95% CI=0.83–1.93), both revealed a
relatively high EBV prevalence (26.19% and 29.93%, respectively)
and both of them included over 500 cases, providing relatively
stable results. In this analysis, BZLF1, Raji and BALF5 showed a 0
detection rate, but the heterogeneity is not significant compared
with Bam H1W. These results support Bam H1W as a good
biomarker for EBV due to the significance of these genes, such as
BZLF1, which is a lytic gene rather than a latent gene. For further
analysis, paired data were extracted from six publications and
analyzed by a McNemar test and a Kappa test (Table 3). The
outcomes were consistent with the former result, indicating that
Bam H1W, Bam H1C and EBER2 were preferred markers for EBV
detection in breast carcinoma tissues used in the PCR assays. This
analysis indicates the importance of the PCR target on the
measured extent of the association of the EBV with breast
carcinoma [40].
The potential relationship between breast cancer and EBV
infection is important because this relationship can not only
broaden our understanding of breast cancer etiology, but also be
applied to early detection of breast cancer [15], as well as breast
cancer prevention and treatment [41]. By pooling the data
published from 1990 to 2010, our study reported the EBV
prevalence rate in breast carcinoma tissues and analyzed certain
parameters related to detecting EBV prevalence in breast cancer
tissues.
To the best of our knowledge, this is the first meta-analysis to
test the association between EBV infection and breast carcinoma.
Moreover, potentially important parameters were evaluated in this
study, including the geographical region, the publication calendar
period, the DNA specimens, the histological types of breast
carcinoma and the detection regions or genes in EBV genome,
which could affect EBV detection in breast carcinoma tissues
[6,10,23]. Our study focuses only on research that tested the
presence of viral particles and does not include immunological
evidence of past or present infection because those studies are too
few to perform an analysis and, in some, the methodology did not
meet our matching criteria [42]. In the future, more attention
should be paid to the immunological evidence of past or present
EBV infection because it may contribute to our understanding of
the relationship between EBV infection and breast cancer risk.
Moreover, the cellular location of the EBV in breast cancer has
become important because EBV-positive infiltrating lymphocytes
might partly explain the presence of the EBV in breast tumors that
show a positive result by PCR but a negative result by ISH or
IHC. Efforts have been made to identify the cellular location of
EBV genetic material in breast cancers. Researchers adopted
microdissection to isolate cancer cells from breast stroma cells and
Epstein-Barr Virus and Sporadic Breast Cancer Risk
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resolve this problem. Reports have shown that EBV DNA has a
higher prevalence in cancer cells than in infiltrating lymphocytes,
and only a proportion of breast cancer tissues test positive for the
EBV [2,10,11,24,26]. Preciado et al. also showed that their EBV
positive result assumed that the cellular source of the PCR EBV
signal came from the epithelial tumor cells because the bystander
lymphocytes of stroma were negative [8]. Alternatively, studies
using laser capture microdissection combined with RT-QPCR
revealed that EBV genomes were heterogeneously distributed in
morphologically identical tumor cells, with some isolated tumor
cells testing negative for EBV-DNA while other clusters of isolated
tumor cells from the same specimen contained relatively high
genome numbers [24].
Limitations
Though our study found a positive correlation between the EBV
and breast cancer, the presence and implication of EBV infection
in the initiation and progression of breast cancer remains
controversial. The conflicting results may be explained by the
use of different technical approaches for detecting the EBV.
Certain technique groups failed to detect the EBV [28,33,35,43–
46], whereas others showed positive results depending on the
methodology applied. For instance, 2 PCR-EBV-negative samples
were stained by EBNA1 MAb in Fawzy’s research [3]. Murray et
al. failed to detect the EBV genome by QPCR though these
samples were EBV positive based on their immunochemistry [27].
The dissimilarities in the sample types (fresh/frozen tissue or
paraffin-embedded tissue), study population (Asian, European,
American, etc.) and heterogeneity among cluster cells could
contribute to this discrepancy. The technical limitations of the
assays were associated with the publication calendar period and
may result in inconsistent outcomes. More studies in this area are
needed to clarify the reasons behind these apparently conflicting
outcomes.
We found only two studies that adopted control groups [6,7]
and matched our selection criteria, of which one [7] was excluded
automatically by the software when we performed meta-analysis.
Though the Begg’s test and Harbord’s weighted linear regression
test proved the publication bias was non-significant, the only study
[6] showing the opposite trend of the other studies might reflect
the difficulties of publishing ‘‘negative’’ results.
Another problem is that though EBV detection in fresh/frozen
tissue showed statistically higher prevalence ratio than in paraffin-
embedded tissue (OR=0.46, 95% CI=0.35–0.61), we did not
find paraffin-embedded tissue and fresh/frozen tissue matched for
the same patients. Therefore, it is difficult to determine whether
fresh or frozen tissue is more suitable for EBV detection. Future
studies that adopt paraffin-embedded tissue and fresh/frozen
tissue matched for the same patients, especially for samples have
been stored for a long period of time, will help us to resolve this
problem and help to understand optimal the conditions for
detecting the EBV in breast cancer tissue.
Our study indicated that an EBV infection is statistically
associated with an increased breast carcinoma risk, especially for
some specific types of carcinoma, such as lobular carcinoma,
according to available publications. EBV infection may play a role
in breast cancer oncogenesis and may result in a more aggressive
phenotype, which is supported by the relative aggressiveness of
EBV-associated breast carcinomas when compared with non-
EBV-associated breast carcinomas [11,27]. A recent study [47]
that use RT-QPCR as a detection technique concurred that EBV-
positive breast cancers presented a more aggressive phenotype. In
this study, there was a difference between EBV-positive and EBV-
negative breast cancers in clinical and biological profiles, and
EBV-positive samples represented a higher proportion among the
high-grade and ER-negative breast cancers. Whether EBV is a
primary etiological agent is unknown. Additional studies, espe-
cially those that include paired non-breast-cancer control groups
and contain larger scale random samples, are needed to achieve
more consistent conclusions regarding the association between
EBV infection and breast carcinoma risk.
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